51
|
Van Middelkoop M, Arden N, Atchia I, Birrell F, Chao J, Lambert R, Ravaud P, Bijlsma J, Doherty M, Dziedzic K, Lohmander S, McAlindon T, Zhang W, Bierma-Zeinstra S. SAT0429 The OA TRIAL Bank: Meta-Analysis of Individual Patient Data Show That Patients with Severe Pain or with Inflammatory Signs Detected by Ultrasound Especially Benefit from Intra-Articular Glucocorticoids for Knee or Hip Oa. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2250] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
52
|
Liu Y, Tundia N, Skup M, Ayyagari R, Du E, Chao J, Mulani P, Bao Y. AB0414 Claims Database Analysis of Adherence to Adalimumab Therapy and Health Care Costs for Patients with Rheumatoid Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
53
|
Barriuso S, Chao J, Jiménez J, García S, González-Carrasco J. Fatigue behavior of Ti6Al4V and 316 LVM blasted with ceramic particles of interest for medical devices. J Mech Behav Biomed Mater 2014; 30:30-40. [DOI: 10.1016/j.jmbbm.2013.10.013] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 10/10/2013] [Accepted: 10/13/2013] [Indexed: 10/26/2022]
|
54
|
Yang L, Chao J, Kook YH, Gao Y, Yao H, Buch SJ. Involvement of miR-9/MCPIP1 axis in PDGF-BB-mediated neurogenesis in neuronal progenitor cells. Cell Death Dis 2013; 4:e960. [PMID: 24336080 PMCID: PMC3877557 DOI: 10.1038/cddis.2013.486] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Revised: 11/04/2013] [Accepted: 11/05/2013] [Indexed: 12/27/2022]
Abstract
Highly conserved microRNA-9 (miR-9) has a critical role in various cellular processes including neurogenesis. However, its regulation by neurotropins that are known to mediate neurogenesis remains poorly defined. In this study, we identify platelet-derived growth factor-BB (PDGF-BB)-mediated upregulation of miR-9, which in turn downregulates its target gene monocyte chemotactic protein-induced protein 1 (MCPIP1), as a key player in modulating proliferation, neuronal differentiation as well as migration of neuronal progenitor cells (NPCs). Results indicate that miR-9-mediated NPC proliferation and neuronal differentiation involves signaling via the nuclear factor-kappa B (NF-κB) and cAMP response element-binding protein (CREB) pathways, and that NPC migration involves CREB but not the NF-κB signaling. These findings thus suggest that miR-9-mediated downregulation of MCPIP1 acts as a molecular switch regulation of neurogenesis.
Collapse
|
55
|
Zhou J, Zhang J, Chao J. Porphyromonas gingivalis promotes monocyte migration by activating MMP-9. J Periodontal Res 2011; 47:236-42. [PMID: 22035412 DOI: 10.1111/j.1600-0765.2011.01427.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND OBJECTIVE The migration of monocytes into the local environment is crucial for their maturation into macrophages or osteoclasts in the pathogenesis of periodontal disease. The objective of this study was to investigate the role and mechanisms mediated by Porphyromonas gingivalis in promoting the migration of monocytes by regulating MMP-9 and TIMP-1 expression. MATERIAL AND METHODS Human THP1 monocytes were treated with culture supernatant derived from P. gingivalis (ATCC 33277) for 24 h. Zymography, western blot analysis and quantitative PCRs were performed to analyse protein and mRNA levels of MMP-9. Protein and mRNA levels of TIMP-1 from monocytes treated with or without P. gingivalis were determined as well. Transwell migration assay was carried out to analyse the effect of P. gingivalis on the migration of human peripheral blood CD14-positive monocytes. An MMP inhibitor (GM6001) and a proteinase inhibitor (leupeptin) were used to determine the role of MMP-9 in P. gingivalis supernatant- and lipopolysaccharide-induced monocyte migration. RESULTS In zymography and western blot, an 82 kDa band of active MMP-9 emerged in P. gingivalis-treated monocyte culture media in a dose-dependent manner, in addition to the MMP-9 proenzyme (92 kDa) band expressed in control cell culture media. P. gingivalis supernatant increased both the protein and the mRNA levels of MMP-9 and TIMP-1. P. gingivalis supernatant, but not its lipopolysaccharide, increased the migratory ability of CD14-positive monocytes. The increased migratory ability of P. gingivalis-treated monocytes was partly inhibited by leupeptin (200 μg/mL) and completely antagonized by the MMP inhibitor GM6001 (100 nm). Lipopolysaccharide of P. gingivalis increased protein and mRNA levels of MMP-9 in monocytes, but had no effect on the migratory ability or MMP-9 activation. CONCLUSION P. gingivalis supernatant increased the migratory ability of monocytes, in part, by increasing activation and expression of MMP-9.
Collapse
|
56
|
Varadarajan P, Lee S, Toro JJ, Schneider D, Chao J, Neumon B, Frye B, Haile DJ, Freytes CO. Longitudinal cohort study of skeletal-related events (SRE) and long-term prognosis in patients with multiple myeloma (MM) with bisphosphonate-related osteonecrosis of the jaw (ONJ). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
57
|
Waliany S, Dieli-Conwright C, Hurria A, Patel S, Frankel PH, Luu TH, Chao J, Mortimer JE. Objective measures of physical fatigue in women undergoing adjuvant therapy for early-stage breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
58
|
Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010; 32:1228-39. [PMID: 20955442 DOI: 10.1111/j.1365-2036.2010.04466.x] [Citation(s) in RCA: 122] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Adalimumab induces and maintains remission in adults with Crohn's disease. AIM To evaluate safety, fistula healing, quality of life and work productivity in adalimumab-treated patients who failed infliximab, including primary nonresponders. METHODS After a ≥8-week infliximab washout, patients with moderate-to-severe Crohn's disease received open-label adalimumab as induction (160/80 mg at weeks 0/2) and maintenance (40 mg every other week) therapies. At/after 8 weeks, patients with flare/nonresponse could receive weekly therapy. Minimum study duration was 8 weeks, continuing until the commercial availability of adalimumab for Crohn's disease. RESULTS Of 673 patients enrolled, 17% were infliximab primary nonresponders and 83% were initial responders. Three percent of patients had serious infections (mainly abscesses). Complete fistula healing was achieved by 34/88 (39%) patients with baseline fistulas. Improvements in quality of life and work productivity were sustained from week 4 to week 24 for all patients, as well as the subgroup of primary nonresponders. CONCLUSIONS Blinded clinical trials have shown adalimumab to be both an effective first-line therapy for anti-TNF-naïve patients and an important treatment option for infliximab-refractory or -intolerant patients. This trial presents open-label experience to support further the safety and effectiveness of adalimumab in patients who failed infliximab therapy, including primary nonresponders (NCT00338650).
Collapse
|
59
|
Bokemeyer B, Schwarz M, Wittig B, Pollack P, Chen N, Mulani P, Chao J, Yang M. Verbesserung der Arbeitsfähigkeit von Morbus Crohn-Patienten durch Adalimumab: Eine Subanalyse deutscher Patienten aus der CARE-Studie. ZEITSCHRIFT FUR GASTROENTEROLOGIE 2010. [DOI: 10.1055/s-0030-1263675] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
60
|
Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D'Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 31:1296-309. [PMID: 20298496 DOI: 10.1111/j.1365-2036.2010.04304.x] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND In the randomized, double-blind, placebo-controlled CHARM trial, adalimumab was more effective than placebo in maintaining clinical remission for patients with moderate-to-severe Crohn's disease (CD) through 56 weeks. AIM To substantiate the long-term safety and clinical benefits of adalimumab through 2 years of therapy in CHARM and its open-label extension (ADHERE). METHODS Patients entering ADHERE on blinded therapy received adalimumab 40 mg every other week (eow). Patients who had already moved to open-label adalimumab eow or weekly in CHARM continued their regimens. Data were analysed by originally randomized treatment group at CHARM baseline (adalimumab 40 mg eow, adalimumab 40 mg weekly, or placebo), regardless of whether patients entered ADHERE or received open-label adalimumab (eow or weekly). RESULTS After up to 2 years of therapy, 37.6%, 41.9% and 49.8% of patients originally randomized to placebo, adalimumab eow and adalimumab weekly, respectively, were in clinical remission. All groups experienced sustained improvements on the Inflammatory Bowel Disease Questionnaire. Decreasing hazard rates for both all-cause and CD-related hospitalizations were observed over time. Over a 2-year period, the rates of serious adverse events and malignancies (33.3 and 1.1 events/100-patient-years respectively) were similar to those observed during the overall adalimumab CD clinical development programme. CONCLUSIONS Adalimumab demonstrated sustained maintenance of clinical remission, improvements in quality of life and reductions in hospitalization during long-term treatment for CD, with no new safety concerns identified.
Collapse
|
61
|
Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010; 31:693-707. [PMID: 20064142 DOI: 10.1111/j.1365-2036.2010.04234.x] [Citation(s) in RCA: 201] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Early onset and complications such as hospitalization and surgery contribute to the economic burden of ulcerative colitis. AIM To review systematically the literature on costs of ulcerative colitis in Western countries. METHODS Studies estimating costs of ulcerative colitis in Western countries were identified using Medline, EMBASE and ISI Web of Science and were rated based on relevance and reliability of estimates. All costs were adjusted to 2008 currency values. A parallel review focused on the impact of disease severity on costs, hospitalizations and surgeries. RESULTS Estimated annual per-patient direct medical costs of ulcerative colitis ranged from $6217 to $11,477 in the United States and from euro8949 to euro10,395 in Europe. Hospitalizations accounted for 41-55% of direct medical costs. Indirect costs accounted for approximately one-third of total costs in the United States and 54-68% in Europe. Total economic burden of ulcerative colitis was estimated at $8.1-14.9 billion annually in the United States and at euro12.5-29.1 billion in Europe; total direct costs were $3.4-8.6 billion in the United States and euro5.4-12.6 billion in Europe. Direct costs, hospitalizations and surgeries increased with worsening disease severity. CONCLUSIONS Ulcerative colitis is a costly disease. Hospitalizations contribute significantly to direct medical costs, and indirect costs are considerable, having previously been substantially underestimated.
Collapse
|
62
|
Nakamura R, Palmer J, Chao J, Stiller T, Pullarkat V, Parker P, Stein A, Snyder D, Cai JL, Bhatia R, Chang K, Wang S, Senitzer D, Forman S, O'Donnell M. Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (RI-HCT) For MDS Using Tacrolimus/Sirolimus As GVHD Prophylaxis. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
63
|
Abstract
Somatic gene delivery approaches have received wide attention as a new technique for studying gene expression and as a potential therapeutic tool in treating both inherited and acquired diseases. Recent studies using nonviral and viral vectors have shown great promise for gene therapy in hypertensive diseases. Potential targets for prospective gene therapy in hypertension include vasopressor renin-angiotensin system components and a number of vasodilator polypeptides such as tissue kallikrein-kinin, atrial natriuretic peptide, adrenomedullin and nitric oxide synthase. Antisense inhibition with oligonucleotides or cDNAs encoding renin, angiotensinogen, angiotensin-converting enzyme and angiotensin receptors has been shown to cause a prolonged blood pressure reduction in spontaneously hypertensive rats. To evaluate the therapeutic potential of vasodilator proteins or peptides in high blood pressure, we delivered the genes encoding human tissue kallikrein, atrial natriuretic peptide, nitric oxide synthase, and adrenomedullin into hypertensive rat models and showed that a single injection resulted in a significant and sustained reduction of blood pressure for several weeks. The potency and duration of blood pressure reduction depends on the dose and the promoter of the gene administered, age and sex of the hypertensive animals as well as the vehicle used for gene delivery. Somatic gene transfer of human tissue kallikrein or atrial natriuretic peptide not only attenuated hypertension but also exerted a protective effect against salt-induced renal damage and cardiac hypertrophy in Dahl salt-sensitive rats after high salt loading. These results suggest that the application of antisense inhibition of vasopressors, or gene delivery of vasodepressors for gene therapy, may have potential in treating human hypertension, and cardiovascular and renal disorders.
Collapse
|
64
|
Gulia J, Gui P, Chao J, Navedo MF, Santana LF, Davis MJ. Roles of c‐Src and PKC in production of persistent calcium sparklet activity. FASEB J 2009. [DOI: 10.1096/fasebj.23.1_supplement.1000.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
65
|
Robinson E, Noone S, Walsh S, Chao J, Nowak-Wegrzyn A. Survey of Patient and Family Preparation and Satisfaction with the Oral Food Challenge (OFC) Experience. J Allergy Clin Immunol 2009. [DOI: 10.1016/j.jaci.2008.12.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
66
|
Xiao S, Chao J, Wang W, Fang F, Qui G, Liu X. Real-time PCR analysis of the heat-shock response of Acidithiobacillus ferrooxidans ATCC 23270. Folia Biol (Praha) 2009; 55:1-6. [PMID: 19445839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
As one of the most important bioleaching bacterial species, Acidithiobacillus ferrooxidans is subjected to different kinds of environmental stress such as temperature changes, presence of some toxic heavy metals or pH changes, which normally take place in bioleaching operations and may affect the activity of the bacteria. To obtain further knowledge of the protective mechanisms employed by A. ferrooxidans in response to elevated growth temperature, temporal gene expression profiles were examined in cells subjected to heat stress by using real-time PCR. The majority of predicted genes, including those encoding chaperones and heat-shock proteins, were significantly up-regulated (P < 0.05 and the fold change >or= 2.0) over a 25-min period after upshift to the heatshock temperature (from 30 to 42 degrees C) and then decrease to readjust their transcript levels to a new steady state at 42 degrees C. Finally, based on the gene expression data and computational analysis, a putative regulatory site having T-T-T-T-T-T-n-n in the -35 region and n-T-A-T-n-A-T-C in the -10 region with average 19 base pairs separating the two elements was predicted upstream of a number of heat-inducible genes.
Collapse
|
67
|
Mulani P, Chao J. Infliximab vs. Adalimumab for Crohn's disease. Aliment Pharmacol Ther 2008; 28:1265-6; author reply 1266-7. [PMID: 18959524 DOI: 10.1111/j.1365-2036.2008.03829.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
68
|
Han J, Liu YL, Fan W, Chao J, Hou YQ, Yin YL, Zhu HL, Meng GQ, Che ZQ. Dietary l-arginine supplementation alleviates immunosuppression induced by cyclophosphamide in weaned pigs. Amino Acids 2008; 37:643-51. [DOI: 10.1007/s00726-008-0184-9] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2008] [Accepted: 09/12/2008] [Indexed: 12/14/2022]
|
69
|
Zhu H, Guo D, Li K, Yan W, Tan Y, Wang X, Treiber FA, Chao J, Snieder H, Dong Y. Prostasin: a possible candidate gene for human hypertension. Am J Hypertens 2008; 21:1028-33. [PMID: 18583984 DOI: 10.1038/ajh.2008.224] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Prostasin, a serine protease, is suggested to be a novel mechanism regulating the epithelial sodium channel (ENaC) expressed in the distal nephron. This study aimed to evaluate whether the human prostasin gene is a novel candidate gene underlying blood pressure (BP) elevation. METHODS In a sample of healthy African-American (AA) and European-American (EA) twin subjects aged 17.6 +/- 3.3 years (n = 920, 45% AAs), race-specific tagging single-nucleotide polymorphisms (tSNPs) were identified to tag all the available SNPs +/- 2 kb up- and downstream of the prostasin gene from HapMap at r2 of 0.8-1.0. Selection yielded four tSNPs in AAs and one in EAs, with one tSNP (rs12597511: C to T) present in both AAs and EAs. RESULTS For rs12597511, CT and TT genotypes exhibited higher systolic BP (SBP) than CC genotype (115.9 +/- 1.1 mm Hg vs. 113.7 +/- 0.6 mm Hg, P = 0.025 (AAs); and 110.7 +/- 0.5 mm Hg vs. 109.6 +/- 0.6 mm Hg, P = 0.115 (EAs)). CT and TT genotypes compared with CC genotype showed a significant increase in diastolic BP (DBP) in both racial groups (62.5 +/- 0.7 mm Hg vs. 60.4 +/- 0.4 mm Hg, P = 0.003 (AAs); and 58.2 +/- 0.3 mm Hg vs. 56.7 +/- 0.4 mm Hg, P = 0.007 (EAs)). Furthermore, there was an increase in radial pulse wave velocity (PWV) in subjects with CT and TT genotype as compared with those with CC genotype (6.5 +/- 0.1 vs. 6.1 +/- 0.1 m/s, P < 0.0001) (EAs); and 6.7 +/- 0.1 vs. 6.6 +/- 0.1 m/s, P = 0.354 (AAs)). Analyses combining AAs and EAs consistently demonstrated a statistical significance of rs12597511 on all the phenotypes including SBP/DBP and PWV. CONCLUSION Genetic variation of the prostasin gene may be implicated in the development of hypertension in youths..
Collapse
|
70
|
Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Somlo G, Sato J, Chow WA. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGF-Rα-expressing Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumors (DSRCT). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
71
|
Loftus E, Colombel J, Panaccione R, Feagan B, Pollack P, Chao J, Mulani P. P078 ADALIMUMAB SUSTAINS QUALITY-OF-LIFE IMPROVEMENTS IN PATIENTS WITH CROHN'S DISEASE: 2-YEAR DATA FROM CHARM. ACTA ACUST UNITED AC 2008. [DOI: 10.1016/s1873-9954(08)70089-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
72
|
Loftus E, Colombel J, Panaccione R, Feagan B, Kamm M, Pollack P, Chao J, Mulani P. P124 SUSTAINABILITY OF ADALIMUMAB IN IMPROVING THE QUALITY OF LIFE OF PATIENTS WITH FISTULIZING CROHN'S DISEASE: 2-YEAR DATA FROM CHARM. ACTA ACUST UNITED AC 2008. [DOI: 10.1016/s1873-9954(08)70135-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
73
|
Yeh Y, Cai Q, Chao J, Russell M. Is more aggressive lymph node assessment associated with improved survival in stage II-III colorectal cancer? Evidence from the Surveillance, Epidemiology and End Results (SEER) cancer registry. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4048 Background: NCCN guidelines recommend assessment of =12 lymph nodes (LN) to improve accuracy in colorectal cancer (CRC) staging. Previous studies have used various cut-points to assess the relationship between the number of LN sampled and survival. The association between NCCN guideline-compliant nodal sampling and survival is assessed, while controlling for other risk factors. Methods: We selected 145,485 adult patients newly diagnosed with stage II or III from SEER during 1990–2003. Kaplan-Meier curves were compared using the log-rank test. Cox proportional hazards models were constructed to determine the effect of sampling ≥ 12 LN on survival. Results: Median patient follow-up was 5.7 years. The table shows overall survival rates in CRC patients with < 12 versus =12 LN assessed: After adjusting for age, sex, tumor size and grade, sampling ≥ 12 LN was independently associated with improved survival. For patients with =12 versus <12 LN assessed, survival increased by 13% for stage IIa [HR=0.75; 95%CI 0.72–0.78; p< .001], 16% for stage IIb [HR=0.69; 95%CI 0.67- 0.71; p< .001], 12% for stage IIIb [HR=0.75; 95%CI 0.72–0.77], and 10% for stage IIIc [HR=0.85, 95%CI 0.81–0.89]. The association was not statistically significant for stage IIIa patients. Conclusion: Consistent with previous reports, this analysis found that optimal nodal sampling increased survival across stage II and III, specifically when ≥ 12 LN are sampled and when controlling for other risk factors. Furthermore, the results underscore the need for adhering to the NCCN guidelines. The lack of a statistically significant association in stage IIIa patients may be due to small cohort size. [Table: see text] [Table: see text]
Collapse
|
74
|
Chao J, Gui P, Zamponi GW, Davis MJ. Spatial Association between L‐type Calcium Channels and Integrins. FASEB J 2007. [DOI: 10.1096/fasebj.21.6.a914-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
75
|
Chen Y, DeVivo M, Chao J. Poster 14. Arch Phys Med Rehabil 2006. [DOI: 10.1016/j.apmr.2006.07.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|